Inicio/Acciones/DERM

DERM

USD

Journey Medical Corporation Common Stock

$9.000+0.590 (7.015%)

Precio en Tiempo Real

Healthcare

Drug Manufacturers - Specialty & Generic

Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado

Fundamentos de la Empresa

Estadísticas de Negociación

Métricas de Mercado

Apertura

$8.410

Máximo

$9.010

Mínimo

$8.260

Volumen

0.22M

Fundamentos de la Empresa

Capitalización de Mercado

236.8M

Industria

Drug Manufacturers - Specialty & Generic

País

United States

Estadísticas de Negociación

Volumen Promedio

0.16M

Bolsa

NCM

Moneda

USD

Rango de 52 Semanas

Mínimo $3.535Actual $9.000Máximo $9.01

Noticias Relacionadas

24 oct 2025 · 12:30

GlobeNewswire

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea

Journey Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology Conference

8 oct 2025 · 12:30

GlobeNewswire

Journey Medical Corporation to Participate in October 2025 Investor Conferences

SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing